Journal of Cardiovascular Translational Research

, Volume 2, Issue 4, pp 368–380

Sudden Death in Hypertrophic Cardiomyopathy

Article

Abstract

Hypertrophic cardiomyopathy (HCM) is regarded as the most common cause of sudden cardiac death in young people (including trained athletes). However, assessing sudden death (SD) risk and identifying the most appropriate candidates for prophylactic device therapy is a complex process compounded by the unpredictability of the underlying arrhythmogenic substrate, absence of a single dominant and quantitative risk maker for this heterogeneous disease, and also the difficulty encountered in assembling sufficiently powered prospective and randomized trials in large patient populations. Patients with multiple risk factors and most young patients with one strong and unequivocal risk marker can be considered candidates for primary prevention defibrillators. Despite certain limitations, the current risk factor algorithm (when combined with a measure of individual physician judgment) has proved to be an effective strategy for targeting high-risk status. This approach has served the HCM patient population well, as evidenced by the significant appropriate defibrillator intervention rates, although a very small proportion of patients without conventional risk factors may also be at risk for SD. Indeed, the introduction of implantable defibrillators to the HCM patient population represents a new paradigm for clinical practice, offering the only proven protection against SD by virtue of effectively terminating ventricular tachycardia/fibrillation. In the process, implantable defibrillators have altered the natural history of HCM, potentially providing the opportunity of normal or near-normal longevity for many patients. Prevention of SD is now an integral, albeit challenging, component of HCM management.

Keywords

Hypertrophic Cardiomyopathy 

References

  1. 1.
    Braunwald, E., Lambrew, C. T., Rockoff, S. D., et al. (1964). Idiopathic hypertrophic subaortic stenosis. I: A description of the disease based upon an analysis of 64 patients. Circulation, 30(suppl IV), 3–217.PubMedGoogle Scholar
  2. 2.
    Maron, B. J. (2002). Hypertrophic cardiomyopathy: A systematic review. JAMA, 287, 1308–1320.CrossRefPubMedGoogle Scholar
  3. 3.
    Maron, B. J., McKenna, W. J., Danielson, G. K., et al. (2003). American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. Journal of the American College of Cardiology, 42, 1687–1713.CrossRefPubMedGoogle Scholar
  4. 4.
    Maron, B. J., Towbin, J. A., Thiene, G., et al. (2006). Contemporary definitions and classification of the cardiomyopathies: An American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation, 113, 1807–1816.CrossRefPubMedGoogle Scholar
  5. 5.
    Spirito, P., Seidman, C. E., McKenna, W. J., et al. (1997). The management of hypertrophic cardiomyopathy. New England Journal of Medicine, 336, 775–785.CrossRefPubMedGoogle Scholar
  6. 6.
    Wigle, E. D., Rakowski, H., Kimball, B. P., et al. (1996). Hypertrophic cardiomyopathy. Clinical spectrum and treatment. Circulation, 92, 1680–1692.Google Scholar
  7. 7.
    Klues, H. G., Schiffers, A., & Maron, B. J. (1995). Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: Morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. Journal of the American College of Cardiology, 26, 1699–1708.CrossRefPubMedGoogle Scholar
  8. 8.
    Maron, M. S., Maron, B. J., Harrigan, C., Buros, J., Gibson, C. M., Olivotto, I., et al. (2009). Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance. Journal of the American College of Cardiology, 54, 220–228.CrossRefPubMedGoogle Scholar
  9. 9.
    Maron, B. J., Gardin, J. M., Flack, J. M., et al. (1995). Assessment of the prevalence of hypertrophic cardiomyopathy in a general population of young adults: Echocardiographic analysis of 4111 subjects in the CARDIA Study. Circulation, 92, 785–789.PubMedGoogle Scholar
  10. 10.
    Maron, M. S., Olivotto, I., Betocchi, S., et al. (2003). Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. New England Journal of Medicine, 348, 295–303.CrossRefPubMedGoogle Scholar
  11. 11.
    Maron, M. S., Olivotto, I., Zenovich, A. G., et al. (2006). Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation, 114, 2232–2239.CrossRefPubMedGoogle Scholar
  12. 12.
    Cecchi, F., Olivotto, I., Gistri, R., et al. (2003). Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. New England Journal of Medicine, 349, 1027–1035.CrossRefPubMedGoogle Scholar
  13. 13.
    Maron, B. J., Shen, W. K., Link, M. S., Epstein, A. E., Almquist, A. K., et al. (2000). Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. New England Journal of Medicine, 342, 365–373.CrossRefPubMedGoogle Scholar
  14. 14.
    Maron, B. J., Spirito, P., Shen, W.-K., Haas, T. S., Formisano, F., Link, M. S., et al. (2007). Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA, 298, 405–412.CrossRefPubMedGoogle Scholar
  15. 15.
    Maron, B. J., & Spirito, P. (2008). Implantable defibrillators and prevention of sudden death in hypertrophic cardiomyopathy. Journal of Cardiovascular Electrophysiology, 19, 1118–1126.CrossRefPubMedGoogle Scholar
  16. 16.
    Seidman, J. G., & Seidman, C. E. (2001). The genetic basis for cardiomyopathy: From mutation identification to mechanistic paradigms. Cell, 104, 557–567.CrossRefPubMedGoogle Scholar
  17. 17.
    Alcalai, R., Seidman, J. G., & Seidman, C. E. (2008). Genetic basis of hypertrophic cardiomyopathy: From bench to the clinics. Journal of Cardiovascular Electrophysiology, 19, 104–110.PubMedGoogle Scholar
  18. 18.
    Bos, J. M., Towbin, J. A., & Ackerman, M. J. (2009). Diagnostic, prognostic, and therapeutic implications of gene testing for hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 54, 201–211.CrossRefPubMedGoogle Scholar
  19. 19.
    Maron, B. J. (2003). Sudden death in young athletes. New England Journal of Medicine, 349, 1064–1075.CrossRefPubMedGoogle Scholar
  20. 20.
    Maron, B. J., Doerer, J. J., Haas, T. S., Tierney, D. M., & Mueller, F. O. (2009). Sudden deaths in young competitive athletes: Analysis of 1866 deaths in the U.S., 1980–2006. Circulation, 119, 1085–1092.CrossRefPubMedGoogle Scholar
  21. 21.
    Spirito, P., Bellone, P., Harris, K. M., et al. (2000). Magnitude of left ventricular hypertrophy predicts the risk of sudden death in hypertrophic cardiomyopathy. New England Journal of Medicine, 342, 1778–1785.CrossRefPubMedGoogle Scholar
  22. 22.
    Maki, S., Ikeda, H., Muro, A., et al. (1998). Predictors of sudden cardiac death in hypertrophic cardiomyopathy. American Journal of Cardiology, 82, 774–778.CrossRefPubMedGoogle Scholar
  23. 23.
    Maron, B. J., Piccininno, M., Casey, S. A., et al. (2003). Relation of extreme left ventricular hypertrophy to age in hypertrophic cardiomyopathy. American Journal of Cardiology, 91, 626–628.CrossRefPubMedGoogle Scholar
  24. 24.
    Maron, B. J., Olivotto, I., Spirito, P., Casey, S. A., Bellone, P., Gohman, T. G., et al. (2000). Epidemiology of hypertrophic cardiomyopathy-related death. Revisited in a large non-referral-based patient population. Circulation, 102, 858–864.PubMedGoogle Scholar
  25. 25.
    Elliott, P. M., Poloniecki, J., Dickie, S., Sharma, S., Monserrat, L., Varnava, A., et al. (2000). Sudden death in hypertrophic cardiomyopathy: Identification of high risk patients. Journal of the American College of Cardiology, 36, 2212–2218.CrossRefPubMedGoogle Scholar
  26. 26.
    Elliott, P. M., Gimeno-Blanes, J. R., Mahon, N. G., Poloniecki, J. D., & McKenna, W. J. (2001). Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet, 357, 420–424.CrossRefPubMedGoogle Scholar
  27. 27.
    Maron, B. J., Estes, N. A. M., III, Maron, M. S., Almquist, A. K., Link, M. S., & Udelson, J. (2003). Primary prevention of sudden death as a novel treatment strategy in hypertrophic cardiomyopathy. Circulation, 107, 2872–2875.CrossRefPubMedGoogle Scholar
  28. 28.
    Maron, B. J., Casey, S. A., Poliac, L. C., Gohman, T. E., Almquist, A. K., & Aeppli, D. M. (1999). Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA, 281, 650–655.CrossRefPubMedGoogle Scholar
  29. 29.
    Maron, B. J., Casey, S. A., Hauser, R. G., et al. (2003). Clinical course of hypertrophic cardiomyopathy with survival to advanced ages. Journal of the American College of Cardiology, 42, 882–888.CrossRefPubMedGoogle Scholar
  30. 30.
    Brock, R. (1957). Functional obstruction of left ventricle (acquired aortic subvalvular stenosis). Guy's Hospital Reports, 106, 221–238.PubMedGoogle Scholar
  31. 31.
    Teare, D. (1958). Asymmetrical hypertrophy of the heart in young athletes. British Heart Journal, 20, 1–8.CrossRefPubMedGoogle Scholar
  32. 32.
    Maron, B. J. (2004). Hypertrophic cardiomyopathy: An important global disease. American Journal of Medicine, 116, 63–65. (Editorial).CrossRefPubMedGoogle Scholar
  33. 33.
    Zou, Y., Song, L., Wang, Z., et al. (2004). Prevalence of idiopathic hypertrophic cardiomyopathy in China: A population-based echocardiographic analysis of 8080 adults. American Journal of Medicine, 115, 14–18.CrossRefGoogle Scholar
  34. 34.
    Maron, B. J., Peterson, E. E., Maron, M. S., & Peterson, J. E. (1994). Prevalence of hypertrophic cardiomyopathy in an outpatient population referred for echocardiographic study. American Journal of Cardiology, 73, 577–580.CrossRefPubMedGoogle Scholar
  35. 35.
    Maron, B. J., Carney, K. P., Lever, H. M., et al. (2003). Relationship of race to sudden cardiac death in competitive athletes with hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 41, 974–980.CrossRefPubMedGoogle Scholar
  36. 36.
    Maron, B. J., & Roberts, W. C. (1979). Quantitative analysis of cardiac muscle cell disorganization in the ventricular septum of patients with hypertrophic cardiomyopathy. Circulation, 59, 689–706.PubMedGoogle Scholar
  37. 37.
    Maron, B. J., Anan, T. J., & Roberts, W. C. (1981). Quantitative analysis of the distribution of cardiac muscle cell disorganization in the left ventricular wall of patients with hypertrophic cardiomyopathy. Circulation, 63, 882–894.PubMedGoogle Scholar
  38. 38.
    Maron, B. J., Wolfson, J. K., Epstein, S. E., & Roberts, W. C. (1986). Intramural (“small vessel”) coronary artery disease in hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 8, 545–557.PubMedGoogle Scholar
  39. 39.
    Maron, B. J., & Zipes, D. P. (2005). 36th Bethesda Conference: Eligibility recommendations for competitive athletes with cardiovascular abnormalities. Journal of the American College of Cardiology, 45, 1312–1375.CrossRefGoogle Scholar
  40. 40.
    Pelliccia, A., Fagard, R., Bjornstad, H. H., et al. (2005). Recommendations for competitive sports participation in athletes with cardiovascular disease. European Heart Journal, 14, 1422–1445.CrossRefGoogle Scholar
  41. 41.
    Spirito, P., Autore, C., Rapezzi, C., Bernabo, P., Badagliacca, R., Maron, M. S., et al. (2009). Syncope and risk of sudden death in hypertrophic cardiomyopathy. Circulation, 119, 1703–1710.CrossRefPubMedGoogle Scholar
  42. 42.
    Nishimura, R. A., & Ommen, S. R. (2007). Hypertrophic cardiomyopathy, sudden death, and implantable cardiac defibrillators: How low the bar? JAMA, 298, 452–454. (Editorial).CrossRefPubMedGoogle Scholar
  43. 43.
    Monserrat, L., Elliott, P. M., Gimeno, J. R., et al. (2003). Nonsustained ventricular tachycardia in hypertrophic cardiomyopathy: An independent marker of sudden death risk in young patients. Journal of the American College of Cardiology, 42, 873–879.CrossRefPubMedGoogle Scholar
  44. 44.
    Olivotto, I., Maron, B. J., Montereggi, A., et al. (1999). Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 33, 2044–2051.CrossRefPubMedGoogle Scholar
  45. 45.
    Adabag, A. S., Casey, S. A., Kuskowski, M. A., et al. (2005). Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 45, 697–704.CrossRefPubMedGoogle Scholar
  46. 46.
    Adabag, A. S., & Maron, B. J. (2007). Implications of arrhythmias and prevention of sudden death in hypertrophic cardiomyopathy. Annals of Noninvasive Electrocardiology, 12, 171–180.CrossRefPubMedGoogle Scholar
  47. 47.
    McKenna, W. J., & Behr, E. R. (2002). Hypertrophic cardiomyopathy: Management, risk stratification, and prevention of sudden death. Heart, 87, 169–176.CrossRefPubMedGoogle Scholar
  48. 48.
    Maron, B. J., Savage, D. D., Wolfson, J. K., & Epstein, S. E. (1981). Prognostic significance of 24-hour ambulatory electrocardiographic monitoring in patients with hypertrophic cardiomyopathy: A prospective study. American Journal of Cardiology, 48, 252–257.CrossRefPubMedGoogle Scholar
  49. 49.
    Maron, M. S., Finley, J. J., Bos, J. M., Hauser, R. H., Manning, W. J., Haas, T. S., et al. (2008). Prevalence, clinical significance and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy. Circulation, 118, 1541–1549.CrossRefPubMedGoogle Scholar
  50. 50.
    Harris, K. M., Spirito, P., Maron, M. S., et al. (2006). Prevalence, clinical profile and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation, 114, 216–225.CrossRefPubMedGoogle Scholar
  51. 51.
    van der Lee, C., ten Cate, F. J., Geleijnse, M. L., et al. (2005). Percutaneous versus surgical treatment for patients with hypertrophic obstructive cardiomyopathy and enlarged anterior mitral valve leaflets. Circulation, 112, 482–488.CrossRefPubMedGoogle Scholar
  52. 52.
    Sorajja, P., Valeti, U., Nishimura, R., Ommen, S. R., Rihal, C. S., Gersh, B. J., et al. (2008). Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation, 118, 131–139.CrossRefPubMedGoogle Scholar
  53. 53.
    Alam, M., Dokainish, H., & Lakkis, N. (2006). Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: A systematic review of published studies. Journal of Interventional Cardiology, 19, 319–327.CrossRefPubMedGoogle Scholar
  54. 54.
    Kimmelstiel, C. D., & Maron, B. J. (2004). Role of percutaneous septal ablation in hypertrophic obstructive cardiomyopathy. Circulation, 109, 452–456.CrossRefPubMedGoogle Scholar
  55. 55.
    Maron, B. J. (2007). Controversies in cardiovascular medicine. Surgical myectomy remains the primary treatment option for severely symptomatic patients with obstructive hypertrophic cardiomyopathy. Circulation, 116, 196–206.CrossRefPubMedGoogle Scholar
  56. 56.
    Batalis, N. I., Harley, R. A., & Collins, K. A. (2005). Iatrogenic deaths following treatment for hypertrophic obstructive cardiomyopathy: Case reports and an approach to the autopsy and death certification. American Journal of Forensic Medicine and Pathology, 26, 343–348.CrossRefPubMedGoogle Scholar
  57. 57.
    Hori, Y., Ueda, M., Nakayama, T., Saegusa, N., Uehara, M., Lee, K., et al. (2007). Occurrence of de novo sustained monomorphic ventricular tachycardia induced after percutaneous transluminal alcohol septal myocardial ablation for hypertrophic obstructive cardiomyopathy. International Journal of Cardiology, 119, 403–407.CrossRefPubMedGoogle Scholar
  58. 58.
    Raute-Kreinsen, U. (2003). Morphology of necrosis and repair after transcoronary ethanol ablation of septal hypertrophy. Pathology, Research and Practice, 1999, 121–127.CrossRefGoogle Scholar
  59. 59.
    Simon, R. D., Crawford, F. A., 3rd, Spencer, W. H., 3rd, & Gold, M. R. (2005). Sustained ventricular tachycardia following alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Pacing and Clinical Electrophysiology, 28, 1354–1356.CrossRefPubMedGoogle Scholar
  60. 60.
    Boltwood, C. M., Jr., Chien, W., & Ports, T. (2004). Ventricular tachycardia complicating alcohol septal ablation. New England Journal of Medicine, 351, 1914–1915.CrossRefPubMedGoogle Scholar
  61. 61.
    Maron, B. J. (2000). Role of alcohol septal ablation in treatment of obstructive hypertrophic cardiomyopathy. Lancet, 355, 425–426. (Editorial).PubMedGoogle Scholar
  62. 62.
    van Dockum, W. G., ten Cate, F. J., ten Berg, J. M., Beek, A. M., Twisk, J. W., Vos, J., et al. (2004). Myocardial infarction after percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: Evaluation by contrast-enhanced magnetic resonance imaging. Journal of the American College of Cardiology, 43, 27–34.CrossRefPubMedGoogle Scholar
  63. 63.
    Valeti, U. S., Nishimura, R. A., Holmes, D. R., Araoz, P. A., Glockner, J. F., Breen, J. F., et al. (2007). Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy. Journal of the American College of Cardiology, 49, 350–357.CrossRefPubMedGoogle Scholar
  64. 64.
    Noseworthy, P. A., Rosenberg, M. A., Fifer, M. A., Palacios, I. F., Lowry, P. A., Ruskin, J. N., et al. (2009). Ventricular arrhythmia following alcohol ablation for obstructive hypertrophic cardiomyopathy. American Journal of Cardiology, 104, 128–132.CrossRefPubMedGoogle Scholar
  65. 65.
    Cuoco, F. A., Spencer, W. H., III, Fernandes, V. L., Nielsen, C. D., Nagueh, S., Sturdivant, J. L., et al. (2008). Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 52, 1718–1723.CrossRefPubMedGoogle Scholar
  66. 66.
    Gilligan, D. M., Chan, W. L., Ang, E. L., & Oakley, C. M. (1991). Effects of a meal on hemodynamic function at rest and during exercise in patients with hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 18, 429–436.PubMedGoogle Scholar
  67. 67.
    Sorajja, P., Ommen, S. R., Nishimura, R. A., Gersh, B. J., Berger, P. B., & Tajik, A. J. (2003). Adverse prognosis of patients with hypertrophic cardiomyopathy who have epicardial coronary artery disease. Circulation, 108, 2342–2348.CrossRefPubMedGoogle Scholar
  68. 68.
    Olivotto, I., Cecchi, F., Casey, S. A., Dolara, A., Traverse, J. H., & Maron, B. J. (2001). Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation, 104, 2517–2524.CrossRefPubMedGoogle Scholar
  69. 69.
    Watkins, H., Rosenzweig, A., Hwang, D. S., Levi, T., McKenna, W., Seidman, C. E., et al. (1992). Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. New England Journal of Medicine, 326, 1108–1114.PubMedCrossRefGoogle Scholar
  70. 70.
    Ackerman, M. J., Van Driest, S. L., Ommen, S. R., et al. (2002). Prevalence and age dependence of malignant mutations in the beta-myosin heavy chain and troponin T genes in hypertrophic cardiomyopathy: A comprehensive outpatient perspective. Journal of the American College of Cardiology, 39, 2042–2048.CrossRefPubMedGoogle Scholar
  71. 71.
    Van Driest, S. L., Ackerman, M. J., Ommen, S. R., et al. (2002). Prevalence and severity of “benign” mutations in the beta-myosin heavy chain, cardiac troponin T, and alpha-tropomyosin genes in hypertrophic cardiomyopathy. Circulation, 106, 3085–3090.CrossRefPubMedGoogle Scholar
  72. 72.
    Maron, B. J., Roberts, W. C., Arad, M., Haas, T. S., Spirito, P., Wright, G. B., et al. (2009). Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy. JAMA, 301, 1253–1259.CrossRefPubMedGoogle Scholar
  73. 73.
    Kelly, M., & Semsarian, C. (2009). Multiple mutations in genetic cardiovascular disease: A marker of disease severity? Circulation: Cardiovascular Genetics, 2, 182–190.CrossRefGoogle Scholar
  74. 74.
    Saumarez, R. C., Pytkowski, M., Sterlinski, M., et al. (2008). Paced ventricular electrogram fractionation predicts sudden cardiac death in hypertrophic cardiomyopathy. European Heart Journal, 29, 1653–1661.CrossRefPubMedGoogle Scholar
  75. 75.
    Basso, C., Thiene, G., Mackey-Bojack, S., Frigo, A. C., Corrado, D., & Maron, B. J. (2009). Myocardial bridging: A frequent component of the hypertrophic cardiomyopathy phenotype lacks systematic association with sudden cardiac death. European Heart Journal, 30, 1627–1634.CrossRefPubMedGoogle Scholar
  76. 76.
    Montgomery, J. V., Harris, K. M., Casey, S. A., et al. (2005). Relation of electrocardiographic patterns to phenotypic expression and clinical outcome in hypertrophic cardiomyopathy. American Journal of Cardiology, 96, 270–275.CrossRefPubMedGoogle Scholar
  77. 77.
    McLoed, C. J., Ackerman, M. J., Nishimura, R. A., et al. (2009). Outcome of patients with hypertrophic cardiomyopathy and a normal electrocardiogram. Journal of the American College of Cardiology, 54, 229–233.CrossRefGoogle Scholar
  78. 78.
    Maron, M. S., Olivotto, I., Maron, B. J., Prasad, S. K., Cecchi, F., Udelson, J. E., et al. (2009). The case for myocardial ischemia in hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 54, 866–875.CrossRefPubMedGoogle Scholar
  79. 79.
    Maron, M. S., Appelbaum, E., Harrigan, C., Buros, J., Gibson, M., Hanna, C. A., et al. (2008). Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy. Circulation: Heart Failure, 1, 184–191.CrossRefGoogle Scholar
  80. 80.
    Adabag, A. S., Maron, B. J., Appelbaum, E., Harrigan, C. J., Buros, J. L., Gibson, C. M., et al. (2008). Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. Journal of the American College of Cardiology, 51, 1369–1374.CrossRefPubMedGoogle Scholar
  81. 81.
    Maron, B. J., Maron, M. S., Lesser, J. R., Hauser, R. G., Haas, T. S., Harrigan, C. T., et al. (2008). Sudden cardiac arrest in hypertrophic cardiomyopathy in the absence of conventional criteria for high risk status. American Journal of Cardiology, 101, 544–547.PubMedGoogle Scholar
  82. 82.
    Melacini, P., Maron, B. J., Bobbo, F., et al. (2007). Evidence that pharmacological strategies lack efficacy for the prevention for sudden death in hypertrophic cardiomyopathy. Heart, 93, 708–710.CrossRefPubMedGoogle Scholar
  83. 83.
    Mirowski, M., Reid, P. R., Mower, M. M., Watkins, L., Gott, V. L., Schauble, J. F., et al. (1980). Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings. New England Journal of Medicine, 303, 322–324.PubMedCrossRefGoogle Scholar
  84. 84.
    Jayatilleke, I., Doolan, A., Ingles, J., et al. (2004). Long-term follow-up of implantable cardioverter defibrillator therapy for hypertrophic cardiomyopathy. American Journal of Cardiology, 93, 1192–1194.CrossRefPubMedGoogle Scholar
  85. 85.
    Woo, A., Monakier, D., Harris, L., et al. (2007). Determinants of implantable defibrillator discharges in high-risk patients with hypertrophic cardiomyopathy. Heart, 93, 1044–1045.CrossRefPubMedGoogle Scholar
  86. 86.
    Maron, B. J., Semsarian, C., Shen, W. K., Link, M. S., Epstein, A. E., Estes, N. A. M., III, et al. (2009). Circadian patterns in the occurrence of malignant ventricular tachyarrhythmias triggering defibrillator interventions in patients with hypertrophic cardiomyopathy. Heart Rhythm, 6, 599–602.CrossRefPubMedGoogle Scholar
  87. 87.
    Kiernan, T. J., Weivoda, P. L., Somers, V. K., Ommen, S. R., & Gersh, B. J. (2008). Circadian rhythm of appropriate implantable cardioverter defibrillator discharges in patients with hypertrophic cardiomyopathy. Pacing and Clinical Electrophysiology, 31, 1253–1258.CrossRefPubMedGoogle Scholar
  88. 88.
    Hauser, R. G., & Maron, B. J. (2005). Lessons from the failure and recall of an implantable cardioverter defibrillator. Circulation, 112, 2040–2042.CrossRefPubMedGoogle Scholar
  89. 89.
    Almquist, A. K., Hanna, C. A., Haas, T. S., & Maron, B. J. (2008). Significance of appropriate defibrillator shock 3 hours and 20 minutes following implantation in a patient with hypertrophic cardiomyopathy. Journal of Cardiovascular Electrophysiology, 19, 319–322.CrossRefPubMedGoogle Scholar
  90. 90.
    Lin, G., Nishimura, R. A., Gersh, B. J., Ommen, S., Ackerman, M., & Brady, P. A. (2009). Device complications and inappropriate implantable cardioverter-defibrillator shocks in patients with hypertrophic cardiomyopathy. Heart, 95, 709–714.CrossRefPubMedGoogle Scholar
  91. 91.
    Sherrid, M. V., & Daubert, J. P. (2008). Risks and challenges of implantable cardioverter-defibrillators in young adults. Progress in Cardiovascular Diseases, 51, 237–263.CrossRefPubMedGoogle Scholar
  92. 92.
    Almquist, A. K., Montgomery, J. V., Haas, T. S., & Maron, B. J. (2005). Cardioverter-defibrillator implantation in high-risk patients with hypertrophic cardiomyopathy. Heart Rhythm, 2, 814–819.CrossRefPubMedGoogle Scholar
  93. 93.
    You, J. J., Woo, A., Ko, D. T., Dameron, D. A., Mihailovic, A., & Krahn, M. (2007). Life expectancy gains and cost-effectiveness of implantable cardioverter/defibrillators for the primary prevention of sudden cardiac death in patients with hypertrophic cardiomyopathy. American Heart Journal, 154, 899–907.CrossRefPubMedGoogle Scholar
  94. 94.
    Goldenberg, I., Moss, A. M., Maron, B. J., Dick, A. W., & Zareba, W. (2005). Cost effectiveness of implanted defibrillators in young people with inherited cardiac arrhythmias. Annals of Noninvasive Electrocardiology, 10(Suppl. 4), 67–83.CrossRefPubMedGoogle Scholar
  95. 95.
    Camm, A., & Nisam, S. (2000). The utilization of the implantable defibrillator—A European enigma. European Heart Journal, 21, 1998–2004.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Hypertrophic Cardiomyopathy CenterMinneapolis Heart Institute FoundationMinneapolisUSA

Personalised recommendations